Table 1 Characteristics of subjects
| Â | Men | Quartile of serum uric acid | Â | Women | Quartile of serum uric acid | Â | Â | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Characteristics | Uric acid range (mg/dL) | UA-1 0.8-4.3 N = 169 | UA-2 4.4-5.5 N = 171 | UA-3 5.6-6.8 N = 163 | UA-4 6.9-16.1 N = 160 | P for trend* | UA-1 0.5-3.8 N = 247 | UA-2 3.9-4.7 N = 213 | UA-3 4.8-6.0 N = 235 | UA-4 6.1-15.4 N = 221 | P for trend* |
Age (years) | 76 ± 8 | 78 ± 7 | 78 ± 8 | 79 ± 7 | 0.004 | 79 ± 8 | 78 ± 8 | 79 ± 8 | 82 ± 8 | < 0.001 | |
Body mass index†(kg/m2) | 21.3 ± 4.6 | 21.9 ± 3.2 | 21.9 ± 3.9 | 21.8 ± 4.0 | 0.372 | 21.2 ± 3.6 | 22.1 ± 3.4 | 22.8 ± 4.8 | 22.3 ± 4.8 | < 0.001 | |
Smoking status‡(never/light/heavy, %) | 26.0/20.7/53.3 | 32.2/19.9/48.0 | 36.2/17.8/46.0 | 35.6/16.9/47.5 | 0.517 | 99.2/0.4/0.4 | 96.2/0.5/3.3 | 65.7/1.3/3.0 | 93.7/2.7/3.6 | 0.043 | |
Alcohol consumption¶, N (%) | 78 (67.8) | 70 (60.9) | 65 (59.1) | 65 (66.3) | 0.470 | 1 (0.6) | 3 (1.8) | 6 (3.3) | 5 (2.8) | 0.286 | |
Systolic blood pressure (mmHg) | 132 ± 22 | 141 ± 22 | 139 ± 24 | 136 ± 25 | 0.003 | 138 ± 21 | 139 ± 20 | 138 ± 21 | 136 ± 28 | 0.552 | |
Diastolic blood pressure (mmHg) | 76 ± 14 | 78 ± 13 | 77 ± 13 | 76 ± 14 | 0.672 | 76 ± 13 | 76 ± 11 | 76 ± 13 | 72 ± 16 | 0.001 | |
Antihypertensive medication, N (%) | 65 (38.5) | 75 (43.9) | 88 (54.0) | 82 (51.3) | 0.019 | 116 (47.0) | 105 (49.3) | 140 (59.6) | 146 (66.1) | < 0.001 | |
Total cholesterol (mg/dl) | 167 ± 46 | 168 ± 42 | 164 ± 41 | 171 ± 45 | 0.505 | 190 ± 40 | 188 ± 42 | 193 ± 43 | 181 ± 44 | 0.025 | |
LDL-cholesterol (mg/dl) | 102 ± 38 | 104 ± 33 | 95 ± 35 | 105 ± 38 | 0.061 | 118 ± 33 | 114 ± 35 | 120 ± 37 | 110 ± 35 | 0.016 | |
Triglyceride (mg/dl) | 68 (52-93) | 73 (56-98) | 76 (57-112) | 89 (69-127) | < 0.001 | 69 (54-93) | 80 (59-109) | 92 (69-124) | 94 (67-120) | < 0.001 | |
HDL-cholesterol (mg/dl) | 49 ± 19 | 47 ± 15 | 51 ± 18 | 45 ± 15 | 0.024 | 57 ± 17 | 56 ± 18 | 53 ± 15 | 51 ± 17 | < 0.001 | |
Antilipidemic drug use, N (%) | 9 (5.3) | 7 (4.1) | 8 (4.9) | 8 (5.0) | 0.959 | 17 (6.9) | 13 (6.1) | 17 (7.2) | 26 (11.8) | 0.115 | |
Fasting plasma glucose (mg/dl) | 119 (98-152) | 112 (95-141) | 113 (96-150) | 115 (96-139) | 0.404 | 112 (97-146) | 108 (94-140) | 109 (92-130) | 118 (97-155) | 0.061 | |
Antidiabetic medication, N (%) | 50 (29.6) | 35 (20.5) | 29 (17.8) | 37 (23.1) | 0.063 | 47 (19.0) | 48 (22.5) | 43 (18.3) | 59 (26.7) | 0.112 | |
Metabolic syndrome, N(%) | 32 (18.9) | 50 (29.2) | 44 (27.0) | 54 (33.8) | 0.022 | 62 (25.1) | 71 (33.3) | 87 (37.0) | 97 (43.9) | < 0.001 | |
Cardiovascular disease, N (%) | 65 (38.5) | 85 (49.7) | 82 (50.3) | 83 (51.9) | 0.055 | 87 (35.2) | 84 (39.4) | 97 (41.3) | 91 (41.2) | 0.448 | |
Ischemic stroke, N (%) | 59 (34.9) | 74 (43.3) | 73 (44.8) | 75 (46.9) | 0.131 | 77 (31.2) | 73 (34.3) | 78 (33.2) | 69 (31.2) | 0.869 | |
Ischemic heart disease, N (%) | 11 (6.5) | 15 (8.8) | 17 (10.4) | 16 (10.0) | 0.592 | 15 (6.1) | 16 (7.5) | 21(8.9) | 30 (13.6) | 0.031 | |